Nasobol®

Acerus Pharmaceuticals Corporation · Phase 2 active Small molecule

At a glance

Generic name	Nasobol®
Sponsor	Acerus Pharmaceuticals Corporation
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Tolerability of an Intra-Nasal Testosterone Product (PHASE2)
NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers (PHASE1)
Influence of Administration Route of Testosterone on Male Fertility (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nasobol® CI brief — competitive landscape report
Nasobol® updates RSS · CI watch RSS
Acerus Pharmaceuticals Corporation portfolio CI